1Baigent C, Keech A, Kearney PM. et al. Efficacy and safety of cholesterol- lowering treatment: Prospective meta- analysis of data from 9 0 0 5 6 parlicipams in 1 4 randomised trials of statins[ J ]. Lancet,2005,366:1267 - 1278.
2Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemie stroke or transient attaek:A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Cardiovascular Radiology and Intervention:The American Academy of Neurology affirms the value of this guideline[J]. Circulation, 2006,113: e409 - e449.
3Plehn JF,Davis BR,Sacks FM,et al. Reduction of stroke incidenee after myocardial infarction with pravastatin:The CholesteroI and Recurrent Events(CARE)study. The Care Investigators[J]. Circulation, 1999,99:216 - 223.
4The Long - Term Intervention with Pravastatin in Ischaemic Disease(LIPID)Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J]. N Engl J Med, 1998, 339:1349 - 1357.
5PPP Project Investigators. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling(PPP)project - a combilled analysis of three largescale randomized trials: Long- term Intervention with Pravastatin in Ischemic Disease(LIPID). Cholesterol and Recurrent Events(CARE), and West of Scotland Coronary Prevention Study(WOSCOPS) [J]. An: J Cardiol, 1995,76 : 899 - 905.
6Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling(PPP)Project[J]. Circulation, 2001,103 : 387 - 392.
7Ridker PM, Cannon CP, Morrow D,et al. C - reactive protein levels and outcomes after statin therapy[J]. N Engl J Med, 2005,352 (1) :20- 28.
8The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High - dose atorvastatin after stroke or transient ischemic attaek[J]. N Engl J Med, 2006, 355 (6) :549 - 559.
9Amarenco P, l.abreuche J, Lavallee P, et a l. Statins in stroke prevention and carotid atherosclerosis:Systematic review and up - todate meta- analysisEJ]. Stroke, 2004,35 (12): 2902 - 2909.
10Wolozin B, Kellman W, Ruosseau P,et al. Decreased prevalence of Alzheimer disease associated with 3 -hydroxy -3 -methyglutaryl coenzyme A reductase inhibitors[J]. Arch Neurol, 2000,57: 1439 - 1443.
3Kim JS, Yoon SS, Kim YH, et al. Serial measurement of interleukin-6,transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke,1996, 27: 1553-1557.
4Vila N, Castillo J, Davalos A, et al. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke,2000, 31: 2325-2329.
5Albert MA, Danielson E, Rifai N, et al . Effect of therapy on C-reactive protein levels, the pravastatin inflammation/CRP evaluation (PRINCE) : a randomized trial and cohort study . JAMA,2001,286:64-70.
6Riesen WF, Engler H, Risch M, et al. Short-term effects of atorvastatin on C-reactive protein. European Heart, 2002,23:794-799.
7Yu H, Rifai N. High-sensitivity C-reactive protein and atherosclerosis:from theory to therapy.Clin Biochem, 2000, 8:601-610.
8Suzuki H, Hayashi T, Tojo SJ, et al. Anti-P-selectin antibody attenuates rat brain ischemic injury. Neurosci Lett, 1999, 265:163-166.
9Connolly ES Jr, Winfree CJ, Prestigiacomo CJ, et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res,1997, 81:304-310.
10Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke, an independent prognostic factor. Stroke,2001, 32:917-924.
7Makihara N, Okada Y, Koga M, et al. Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry[J]. Cerebrovasc Dis, 2012, 33(3):240-247.
